IBERE PHARMACEUTICALS

Overview

• IndustryBlank Checks¹
• HeadquartersPhiladelphia, Pennsylvania¹
• Incorporated inCayman Islands³
• Business address2005 Market Street, Suite 2030, Philadelphia, Pa 19103³
• Filer category, Emerging growth company³

See how the biggest companies compare on our leaderboards

Corporate structure

IBERE PHARMACEUTICALS sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IBERE PHARMACEUTICALS reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Leadership

Who has led IBERE PHARMACEUTICALS, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerOsagie O. Imasogie Feb 25, 2021 to Feb 25, 2021⁷
• Chief financial officerLisa M. Gray Feb 25, 2021 to Feb 25, 2021⁸
• Chief operating officerZoltan Kerekes Feb 25, 2021 to Feb 25, 2021⁹

Timeline

1. Feb 15, 20238-K Other events¹⁴
2. Feb 25, 2021New chief executive Osagie O. Imasogie becomes CEO⁷

Filings

15 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 1 major events, 8 large holders, 1 other. The latest 15:

1. Mar 13, 202315-12G EDGAR
2. Feb 15, 20238-K EDGAR
3. Feb 14, 2023SC 13G/A EDGAR
4. Feb 14, 2023SC 13G EDGAR
5. Feb 8, 2023SC 13G IBER 13G EDGAR
6. Feb 8, 2023SC 13G/A SCHEDULE 13G (AMENDMENT NO. 1) EDGAR
7. Feb 2, 2023SC 13G/A EDGAR
8. Nov 14, 202210-Q EDGAR
9. Aug 12, 202210-Q EDGAR
10. May 16, 202210-Q EDGAR
11. Mar 31, 202210-K EDGAR
12. Feb 14, 2022SC 13G/A IBERE PHARMACEUTICALS EDGAR
13. Feb 8, 2022SC 13G EDGAR
14. Jan 14, 2022SC 13G SCHEDULE 13G EDGAR
15. Nov 12, 202110-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• CITADEL ADVISORS LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023¹⁵
• GLAZER CAPITAL, LLCSC 13G, 1 filing Feb 14, 2023¹⁶
• Hartree Partners, LPSC 13G/A, 1 filing Feb 8, 2023¹⁷
• Hudson Bay Capital Management LPSC 13G, 1 filing Feb 8, 2023¹⁸
• Magnetar Financial LLCSC 13G/A, 2 filings Jan 14, 2022 to Feb 2, 2023¹⁹
• PIPV Capital LLCSC 13G, 1 filing Feb 8, 2022²⁰

SEC filer profile

How IBERE PHARMACEUTICALS is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARIBERE PHARMACEUTICALS¹
• CIK0001835205
• Employer ID (EIN)98-1564986¹
• Filer status<br>emerging growth company¹
• Incorporated inCayman Islands¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)6770 Blank Checks¹
• Business address2005 Market Street, Suite 2030, Philadelphia, PA 19103¹
• Phone267-765-3222¹
• Public float$133.3M as of Jun 30, 2021²
• On EDGAR sinceDec 7, 2020¹
• Filings51 in all: 3 (8), 10-Q (6), 8-K (6), SC 13G (6), CORRESP (4), SC 13G/A (4), 10-K (1), 10-Q/A (1)¹
  All 23 form types

  15-12G (1), 25-NSE (1), 4 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRSLTR (1), EFFECT (1), NT 10-Q (1), S-1 (1), S-1/A (1), S-1MEF (1), UPLOAD (1)

• Latest filingsAnnual report (10-K) Mar 31, 2022
  Quarterly report (10-Q) Nov 14, 2022
  Latest 8-K (8-K) Feb 15, 2023